TRERNA1: TRERNA1 is a long non-coding RNA (lncRNA) that has been found to be upregulated in colorectal cancer (CRC) tissues compared to normal tissues [PMC7204641]. It has also been identified as overexpressed in chronic lymphocytic leukemia (CLL) and associated with poor prognosis [PMC5432228]. In diffuse large B-cell lymphoma (DLBCL), TRERNA1 has been shown to exhibit higher expression in DLBCL tissues compared to normal lymph node hyperplasia tissues and can promote cell proliferation both in vitro and in vivo [PMC8760254]. Additionally, TRERNA1 can be modified by ALKBH5, with the upregulation of ALKBH5 promoting the expression of TRERNA1. The N6-methyladenosine-modified TRERNA1 mediated by ALKBH5 has been found to promote the occurrence of DLBCL [PMC10003095]. Furthermore, TRERNA1 has been shown to decrease cell apoptosis, while miR-23a increases cell apoptosis [PMC8973726]. In studies involving TRERNA1 knockdown in SU-DHL4 cells, it was found that p21 expression was promoted [PMC8760254]. The expression levels of TRERNA1 and miR-23a were normalized using internal controls 18S rRNA and U6 [PMC8973726]. In summary, TRERNA1 is a lncRNA that is upregulated in CRC tissues compared to normal tissues. It is also overexpressed in CLL and associated with poor prognosis. In DLBCL, it exhibits higher expression and promotes cell proliferation. Additionally, it can be modified by ALKBH5 and its N6-methyladenosine modification mediated by ALKBH5 promotes the occurrence of DLBCL. Furthermore, it affects cell apoptosis and its knockdown promotes p21 expression. The expression levels of TRERNA1 and miR-23a are normalized using internal controls 18S rRNA and U6.